Mar 3, 2017
Actelion re-enters talks with J&J, sidelining Sanofi ZURICH/FRANKFURT (Reuters) - Swiss biotech company Actelion (ATLN.S) has turned back to prospective bidder Johnson & Johnson (JNJ.N) for exclusive talks about a "strategic transaction", in an about-turn that appears to sideline rival suitor Sanofi (SASY.PA). Actelion said in a brief statement Sourced through Scoop.it from: finance.yahoo.com